Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report), Zymeworks (ZYME – Research Report) and Aclaris Therapeutics (ACRS – Research Report).
Avadel Pharmaceuticals (AVDL)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Avadel Pharmaceuticals today and set a price target of $21.00. The company’s shares closed last Friday at $10.66.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
Currently, the analyst consensus on Avadel Pharmaceuticals is a Strong Buy with an average price target of $21.00, implying an 88.3% upside from current levels. In a report issued on November 9, Needham also maintained a Buy rating on the stock with a $19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Zymeworks (ZYME)
H.C. Wainwright analyst Robert Burns reiterated a Hold rating on Zymeworks today and set a price target of $8.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Zymeworks with a $9.00 average price target, implying a 28.8% upside from current levels. In a report issued on November 7, Leerink Partners also maintained a Hold rating on the stock with a $9.00 price target.
Aclaris Therapeutics (ACRS)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics, with a price target of $43.00. The company’s shares closed last Friday at $4.76, close to its 52-week low of $4.33.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aclaris Therapeutics with a $28.67 average price target, which is a 491.1% upside from current levels. In a report issued on November 7, Leerink Partners also maintained a Buy rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVDL:
- Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Avadel Pharmaceuticals reports Q3 EPS (41c), consensus (37c)
- AVDL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
- Avadel Pharmaceuticals announces data supporting clinical profile for LUMRYZ
